A notable advancement in glucose treatment is emerging with the approval of tirzepatide at a dosage of 45mg. This innovative version builds upon the existing success of tirzepatide, a dual GIP and GLP-1 agonist, and https://bookmarkswing.com/story23046816/groundbreaking-approach-tirzepatide-45mg-for-glucose-control